Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Greenway A, Ware RE, Thornburg CD. Greenway A, et al. Am J Hematol. 2011 Apr;86(4):357-61. doi: 10.1002/ajh.21986. Am J Hematol. 2011. PMID: 21442640
Children with sickle cell anemia (SCA) and a primary overt stroke are at high risk of recurrent (secondary) stroke. Chronic transfusion therapy dramatically reduces but does not eliminate this high risk, and inevitably results in transfusion-related hemosiderosis. ...With …
Children with sickle cell anemia (SCA) and a primary overt stroke are at high risk of recurrent (secondary) stroke. Chronic transfusi …
Hospitalisations for sickle-cell disease in an Australian paediatric population.
Teoh Y, Greenway A, Savoia H, Monagle P, Roy J, Barnes C. Teoh Y, et al. Among authors: greenway a. J Paediatr Child Health. 2013 Jan;49(1):68-71. doi: 10.1111/jpc.12018. Epub 2012 Dec 2. J Paediatr Child Health. 2013. PMID: 23198729
METHODS: This was a retrospective chart review of SCD patients who presented to the Royal Children's Hospital over a 10.5-year period. ...The population was made up of 28 homozygous sickle-cell disease, 1 sickle C disease and 8 sickle-cell beta patients from a
METHODS: This was a retrospective chart review of SCD patients who presented to the Royal Children's Hospital over a 10.5-year …
Vitamin D status of chronically ill or disabled children in Victoria.
Greenway A, Zacharin M. Greenway A, et al. J Paediatr Child Health. 2003 Sep-Oct;39(7):543-7. doi: 10.1046/j.1440-1754.2003.00211.x. J Paediatr Child Health. 2003. PMID: 12969211
METHODOLOGY: A group of inpatients at the Royal Children's Hospital, Melbourne, Victoria, as identified by the primary unit, were sampled to measure serum vitamin D and parameters of bone turnover. A second group of disabled children (outpatients) were also measured …
METHODOLOGY: A group of inpatients at the Royal Children's Hospital, Melbourne, Victoria, as identified by the primary unit, were sam …
Neonatal thrombosis and its treatment.
Greenway A, Massicotte MP, Monagle P. Greenway A, et al. Blood Rev. 2004 Jun;18(2):75-84. doi: 10.1016/S0268-960X(03)00042-0. Blood Rev. 2004. PMID: 15010146 Review.
Transfusion service management of sickle-cell disease patients.
Yazer MH, Lozano M, Crighton G, Greenway A, Comande M, Savoia H, Wood E, Gilli S, Castilho L, Saad ST, Galactéros F, Noizat-Pirenne F, Pazgal I, Stark P, Orlin Y, Perseghin P, Masera N, Cela E, Anguita J, Wikman A, Delaney M. Yazer MH, et al. Among authors: greenway a. Vox Sang. 2016 Apr;110(3):288-94. doi: 10.1111/vox.12296. Epub 2015 Jul 14. Vox Sang. 2016. PMID: 26177989 No abstract available.
Congenital Methemoglobinemia Type II-Clinical Improvement with Short-Term Methylene Blue Treatment.
Cooper MS, Randall M, Rowell M, Charlton M, Greenway A, Barnes C. Cooper MS, et al. Among authors: greenway a. Pediatr Blood Cancer. 2016 Mar;63(3):558-60. doi: 10.1002/pbc.25791. Epub 2015 Nov 17. Pediatr Blood Cancer. 2016. PMID: 26574897
We report a case of prophylactic management with methylene blue (MB) in an almost 4-year-old male with congenital methemoglobinemia type II. He has a CYB5R3 compound heterozygote mutation, causing a cytochrome-b(5) reductase deficiency. Since the MB treatment …
We report a case of prophylactic management with methylene blue (MB) in an almost 4-year-old male with congenital methemoglobinemia t …
Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients.
Cheng DR, Barton R, Greenway A, Crawford NW. Cheng DR, et al. Among authors: greenway a. Expert Rev Vaccines. 2016 Dec;15(12):1567-1574. doi: 10.1080/14760584.2016.1193438. Epub 2016 Jun 13. Expert Rev Vaccines. 2016. PMID: 27216827 Review.
Rituximab is a chimeric anti-CD 20 monoclonal antibody that is an immunosuppressant affecting both cellular and humoral immunity. ...Expert commentary: The increasing use of rituximab in a variety of novel areas within pediatrics must be accompanied by informed disc …
Rituximab is a chimeric anti-CD 20 monoclonal antibody that is an immunosuppressant affecting both cellular and humoral immunity. ... …
Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95).
Greenway A, Ignjatovic V, Summerhayes R, Newall F, Burgess J, DeRosa L, Monagle P. Greenway A, et al. Thromb Haemost. 2009 Jul;102(1):159-65. doi: 10.1160/TH09-01-0056. Thromb Haemost. 2009. PMID: 19572081 Clinical Trial.
A new POC system, the CoaguChek XS has recently been developed to measure the international normalised ratio (INR) and may offer significant advantages. ...The laboratory gold standard, a manual prothrombin time with reference thromboplastin (rTF/95) was additionall
A new POC system, the CoaguChek XS has recently been developed to measure the international normalised ratio (INR) and may offer sign
MRA versus angiogram for the diagnosis of peripheral arterial disease, a case report.
Sakar S, Greenway A, Newell F, Fasulakis S, Monagle P. Sakar S, et al. Among authors: greenway a. Thromb Res. 2003;112(1-2):43-5. doi: 10.1016/j.thromres.2003.11.003. Thromb Res. 2003. PMID: 15013272 No abstract available.
Platelet dysfunction and increased bleeding tendency in McCune-Albright syndrome.
Bajpai A, Greenway A, Zacharin M. Bajpai A, et al. Among authors: greenway a. J Pediatr. 2008 Aug;153(2):287-9. doi: 10.1016/j.jpeds.2008.02.045. J Pediatr. 2008. PMID: 18639732
71 results
Jump to page
Feedback